| 763738 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids |
2021-11-01 |
10.1136/jitc-2021-003213 |
Meng Qingda, Xie Shanshan, Gray G Kenneth, Dezfulian Mohammad H, Li Weilin, Huang Ling, Akshinthala Dipikaa, Ferrer Elizabeth, Conahan Catherine, Perea Del Pino Sofia, Grossman Joseph, Elledge Stephen J, Hidalgo Manuel, Muthuswamy Senthil K |
| 763737 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release |
2021-11-01 |
10.1136/jitc-2021-003616 |
Aschmoneit Nadine, Kühl Lennart, Seifert Oliver, Kontermann Roland E |
| 763736 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival |
2021-11-01 |
10.1136/jitc-2021-003188corr1 |
|
| 763735 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy? |
2021-11-01 |
10.1136/jitc-2021-003154corr1 |
|
| 763734 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy |
2021-11-01 |
10.1136/jitc-2020-000867corr1 |
|
| 763733 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial |
2021-11-01 |
10.1136/jitc-2021-003156 |
Klein Oliver, Kee Damien, Gao Bo, Markman Ben, da Gama Duarte Jessica, Quigley Luke, Jackett Louise, Linklater Richelle, Strickland Andrew, Scott Clare, Mileshkin Linda, Palmer Jodie, Carlino Matteo, Behren Andreas, Cebon Jonathan |
| 763732 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML |
2021-11-01 |
10.1136/jitc-2021-002968corr1 |
|
| 763731 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma |
2021-11-01 |
10.1136/jitc-2020-001806corr1 |
|
| 763730 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial |
2021-11-01 |
10.1136/jitc-2021-003290 |
Hua Yijun, You Rui, Wang Zhiqiang, Huang Peiyu, Lin Mei, Ouyang Yanfeng, Xie Yulong, Zou Xiong, Liu Youping, Duan Chongyang, Liu Yonglong, Gu Chenmei, Liu Rongzeng, Yang Qi, Jiang Rou, Zhang Mengxia, Ding Xi, Chen Siyuan, Lin Chao, Sun Rui, Chen Mingyuan |
| 763729 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis |
2021-11-01 |
10.1136/jitc-2021-002553corr1 |
|
